Investigational drug for advanced Non-Small Cell Lung Cancer

Trial ID:
IRB-16-6885
Michael P. Kosty, M.D.
This study will compare the safety and effectiveness of an investigational drug called nivolumab, in combination with other drugs already used to treat advanced non-small cell lung cancer (NSCLC). Nivolumab is an antibody (a type of human protein) that might allow the body’s immune system to work against tumor cells.

Inclusion Criteria

  • Be 18 years of age or older
  • Have recurrence of locally advanced or Stage 4 NSCLC
  • Have tumor with positive EGFR mutation and negative ALK translocation mutation

Exclusion Criteria

  • Have received treatment for local NSCLC less than 6 months prior to disease recurrence
  • Have received treatment for recurrence of locally advanced or Stage 4 NSCLC
  • Be pregnant, planning to become pregnant, or breastfeeding
  • Have a positive test for hepatitis B virus, hepatitis C virus, or a history of HIV virus infection

Additional Info

  • Patients in this study will be assigned by chance to receive either nivolumab with erlotinib OR erlotinib alone.

Contact Info: